AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02385474
Drug: 12% SDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
Trial: NCT02385474
Drug: 38% SDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
Trial: NCT04951869
Drug: Protescal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
Trial: NCT03744247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously every 2 weeks
Trial: NCT00870844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vials with solution for IV infusion
Trial: NCT03732963
Drug: Melatonin (Group M)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
Trial: NCT00366795
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration once daily
Trial: NCT03906799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
Trial: NCT00128440
Drug: BEA 2180 BR
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00542633
Drug: VIAject™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage as individually required
Trial: NCT00542633
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage as individually required
Trial: NCT01593397
Drug: Propofol and Fentanyl administration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
Trial: NCT02735902
Drug: Vitamin K antagonist or direct oral anticoagulant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg
Trial: NCT01982682
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03164876
Drug: AUT00206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
Trial: NCT03164876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of placebo, twice daily, to take orally with food for 4 weeks
Trial: NCT03860974
Drug: Serratus Plane block (single injection)
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
Trial: NCT00064987
Drug: gonadotropin releasing hormone (GnRH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
Trial: NCT02969382
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Placebo capsule daily for 4 weeks
Trial: NCT00005985
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02088697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02439216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03073876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
Trial: NCT01050530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration of placebo after breakfast for 7 days
Trial: NCT01750190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00911300
Drug: Vitamin-K-Antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different drugs
Trial: NCT01366118
Drug: Therapeutic target tailored chemotherapy
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.~Ch combination schema was customized based on:~Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.~When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen
Trial: NCT01514461
Drug: LCQ908
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Trial: NCT01514461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Trial: NCT02532686
Drug: DAAOI-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-2000mg/d, oral, for 6 weeks
Trial: NCT02532686
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, for 6 weeks
Trial: NCT03423797
Drug: 25% AgNO3 solution followed by 5% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
Trial: NCT03423797
Drug: 25% AgNO3 solution followed by 5% NaF with fTCP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
Trial: NCT03901313
Drug: Treatment B - 400 mg Fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
Trial: NCT03901313
Drug: Treatment C - 200 mg Fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
Trial: NCT03864419
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03864419
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03864419
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03864419
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02476019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously
Trial: NCT02963779
Drug: LY2775240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02963779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04089449
Drug: PRT811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT811 will be administered orally
Trial: NCT06251440
Drug: Fetal Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under ultrasound guidance, intracardiac injection of 0.2 to 3.0 ml of 15% weight/volume (2 miliequivalent/mililiter ) potassium chloride (KCl) was administered via transabdominal route
Trial: NCT01349192
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: \< 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day.
Trial: NCT03919656
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
Trial: NCT03992365
Drug: Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets.
Trial: NCT02608411
Drug: ARQ197
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04139824
Drug: Xanthine Oxidase Inhibitor
RxNorm normalized name: Xanthine oxidase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC350189 200mg qd
Trial: NCT04139824
Drug: nonsteroidal anti-inflammatory drug
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg BID
Trial: NCT00199017
Drug: Dexamethasone/Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00199017
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01223378
Drug: BOL-303259-X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution, various concentrations, once daily (QD) 28 days
Trial: NCT01870778
Drug: RLX030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/mL solution in 6 mL vials
Trial: NCT01870778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo solution to serelaxin
Trial: NCT00399061
Drug: Systane, Optive, Restasis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
Trial: NCT01096472
Drug: LAS41003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT00862043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo t.i.d.
Trial: NCT00470314
Drug: L-Ornithine L-Aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04257487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic sulodexide 250 LSU
Trial: NCT06188221
Drug: Corticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
Trial: NCT03709706
Drug: Lete-cel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lete-cel will be administered to eligible participants.
Trial: NCT00649272
Drug: Ditropan XL® Extended-release tablets, 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, single dose fasting
Trial: NCT01099566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
Trial: NCT02803749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03234374
Drug: Marcaine 0.25% infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
Trial: NCT01100151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT03944200
Drug: DA-1229_01(A), Sugamet SR Tab 5/1000mg®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
Trial: NCT03944200
Drug: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
Trial: NCT00347061
Drug: afuzosin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04241640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02798653
Drug: Choriomon® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
Trial: NCT02798653
Drug: Choriomon® injection+Endometrin ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
Trial: NCT02798653
Drug: Endometrin ® vaginal tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
Trial: NCT04146103
Drug: Novex
RxNorm normalized name: Synovex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
Trial: NCT01506388
Drug: Vaginal IMN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMN vaginal 40 mg every 4-6 hours
Trial: NCT02961998
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients from experimental group will take celecoxib, except for sorafenib
Trial: NCT04174339
Drug: POF
RxNorm normalized name: Ta-Poff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Trial: NCT03516656
Drug: Standard heparin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be placed on heparin infusions per their surgeon's discretion.
Trial: NCT03516656
Drug: Real time heparin dose adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
Trial: NCT01042093
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 1 mg/ml (0.5 ml)
Trial: NCT00297076
Drug: GW873140
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01790087
Drug: ANX-188 Therapeutic Dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01565889
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
Trial: NCT01565889
Drug: EFV/FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
Trial: NCT01565889
Drug: ZDV/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
Trial: NCT01565889
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TDF (200/300 mg) FDC tablet administered orally once daily
Trial: NCT01565889
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
Trial: NCT00810147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, once daily, 24 weeks
Trial: NCT03248427
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 as a continuous IV perfusion
Trial: NCT03248427
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 MG/M2 in a 30 minutes IV infusion
Trial: NCT00051948
Drug: TLK286
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00185289
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
Trial: NCT00999986
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg oral per day for 7 days
Trial: NCT00238966
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02565680
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xyzall 5mg during 5 days + placebo 40mg during 4 days
Trial: NCT03591874
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
Trial: NCT00695344
Drug: azathioprine or mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 times per day during 2 years
Trial: NCT02477644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, per os, 300 mg twice daily.
Trial: NCT00127114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00894621
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
Trial: NCT00894621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01710787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 unilateral intranasal sprays per dose
Trial: NCT01467297
Drug: ceftidoren
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftidoren 200 mg bid for 5 days
Trial: NCT03408639
Drug: CinnaPoietin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
Trial: NCT03408639
Drug: Eprex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
Trial: NCT03408639
Drug: Nephrovit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephrovit tablet is daily administered to all the patients.
Trial: NCT03766295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01026194
Drug: Placebo / Teneli (Teneligliptin) + pio (pioglitazone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
Trial: NCT01026194
Drug: Teneli / Teneli + pio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.